NASDAQ:BPTH
Bio-Path Holdings Stock News
$2.61
-0.0500 (-1.88%)
At Close: May 03, 2024
Bio-Path Holdings: Q4 Earnings Insights
12:49pm, Friday, 11'th Mar 2022 Benzinga
Bio-Path Holdings (NASDAQ: BPTH ) reported its Q4 earnings results on Friday, March 11, 2022 at 07:00 AM. Here''s what investors need to know about the announcement. Earnings Bio-Path Holdings missed estimated earnings by 84.37%, reporting … Full story available on Benzinga.com
Bio-Path GAAP EPS of -$1.55 misses by $0.27
12:03pm, Friday, 11'th Mar 2022 Seeking Alpha
Bio-Path press release (BPTH): FY GAAP EPS of -$1.55 misses by $0.27.As of December 31, 2021, the company had cash of $23.8M; Net cash used in operating activities for the year…
Bio-Path Holdings Reports Full Year 2021 Financial Results
12:00pm, Friday, 11'th Mar 2022 GlobeNewswire Inc.
Conference Call to be Held Today at 8:30 A.M. ET Conference Call to be Held Today at 8:30 A.M. ET
Bio-Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q4 2021 Results - Earnings Call Transcript
11:01am, Friday, 11'th Mar 2022
Bio-Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q4 2021 Results - Earnings Call Transcript
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
09:30pm, Tuesday, 08'th Mar 2022 GlobeNewswire Inc.
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to de
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
09:30pm, Tuesday, 08'th Mar 2022 GlobeNewswire
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting, taking place in Atlanta, GA on April 8-13, 2022.
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
04:30pm, Tuesday, 08'th Mar 2022
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to deve
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
12:00pm, Friday, 04'th Mar 2022 GlobeNewswire Inc.
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
12:00pm, Friday, 04'th Mar 2022 GlobeNewswire
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize ® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 11, 2022 at 8:30 a.m. ET to report financial results for the full year ended December 31, 2021 and to provide a business overview.
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
07:00am, Friday, 04'th Mar 2022
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p
Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
12:00pm, Wednesday, 05'th Jan 2022 GlobeNewswire Inc.
HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a
Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
07:00am, Wednesday, 05'th Jan 2022
HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a p
Bio-Path Holdings Presents Data from Ongoing Phase 2 Study of Prexigebersen at 2021 American Society of Hematology Annual Meeting
12:00pm, Monday, 13'th Dec 2021 GlobeNewswire Inc.
Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients Preliminary Prexigebersen Data Show Signs of Safety and Efficacy in High Risk AML Patients
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
11:07am, Monday, 06'th Dec 2021 Benzinga
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r
Brokerages Anticipate Bio-Path Holdings, Inc. (NASDAQ:BPTH) to Announce -$0.32 EPS
09:32pm, Monday, 22'nd Nov 2021 Transcript Daily
Analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH) to post earnings of ($0.32) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Bio-Paths earnings. The highest EPS estimate is ($0.29) and the lowest is ($0.35). Bio-Path posted earnings of ($0.57) per share during the same quarter last year, []